Pak Fah Yeow International Limited

SEHK:239 Voorraadrapport

Marktkapitalisatie: HK$785.3m

Pak Fah Yeow International Inkomsten in het verleden

Verleden criteriumcontroles 3/6

Pak Fah Yeow International has been growing earnings at an average annual rate of 42.9%, while the Pharmaceuticals industry saw earnings growing at 5.7% annually. Revenues have been growing at an average rate of 14.9% per year. Pak Fah Yeow International's return on equity is 12.8%, and it has net margins of 36.3%.

Belangrijke informatie

42.9%

Groei van de winst

42.9%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie5.6%
Inkomstengroei14.9%
Rendement op eigen vermogen12.8%
Nettomarge36.3%
Laatste winstupdate30 Jun 2024

Recente prestatie-updates uit het verleden

Why Pak Fah Yeow International's (HKG:239) Earnings Are Better Than They Seem

Sep 19
Why Pak Fah Yeow International's (HKG:239) Earnings Are Better Than They Seem

Recent updates

Why Pak Fah Yeow International's (HKG:239) Earnings Are Better Than They Seem

Sep 19
Why Pak Fah Yeow International's (HKG:239) Earnings Are Better Than They Seem

Pak Fah Yeow International (HKG:239) Is Paying Out A Dividend Of HK$0.095

Aug 30
Pak Fah Yeow International (HKG:239) Is Paying Out A Dividend Of HK$0.095

Here's Why We Think Pak Fah Yeow International (HKG:239) Might Deserve Your Attention Today

Nov 21
Here's Why We Think Pak Fah Yeow International (HKG:239) Might Deserve Your Attention Today

Estimating The Intrinsic Value Of Pak Fah Yeow International Limited (HKG:239)

Aug 31
Estimating The Intrinsic Value Of Pak Fah Yeow International Limited (HKG:239)

Calculating The Intrinsic Value Of Pak Fah Yeow International Limited (HKG:239)

Jun 01
Calculating The Intrinsic Value Of Pak Fah Yeow International Limited (HKG:239)

Does Pak Fah Yeow International (HKG:239) Have A Healthy Balance Sheet?

Dec 12
Does Pak Fah Yeow International (HKG:239) Have A Healthy Balance Sheet?

Pak Fah Yeow International's (HKG:239) Shareholders Will Receive A Smaller Dividend Than Last Year

Sep 02
Pak Fah Yeow International's (HKG:239) Shareholders Will Receive A Smaller Dividend Than Last Year

The Strong Earnings Posted By Pak Fah Yeow International (HKG:239) Are A Good Indication Of The Strength Of The Business

Sep 24
The Strong Earnings Posted By Pak Fah Yeow International (HKG:239) Are A Good Indication Of The Strength Of The Business

Pak Fah Yeow International (HKG:239) Will Pay A Larger Dividend Than Last Year At HK$0.028

Aug 28
Pak Fah Yeow International (HKG:239) Will Pay A Larger Dividend Than Last Year At HK$0.028

Estimating The Intrinsic Value Of Pak Fah Yeow International Limited (HKG:239)

May 11
Estimating The Intrinsic Value Of Pak Fah Yeow International Limited (HKG:239)

Consider This Before Buying Pak Fah Yeow International Limited (HKG:239) For The 2.9% Dividend

Feb 21
Consider This Before Buying Pak Fah Yeow International Limited (HKG:239) For The 2.9% Dividend

What Type Of Returns Would Pak Fah Yeow International's(HKG:239) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Dec 17
What Type Of Returns Would Pak Fah Yeow International's(HKG:239) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

How Does Pak Fah Yeow International Limited (HKG:239) Fare As A Dividend Stock?

Nov 21
How Does Pak Fah Yeow International Limited (HKG:239) Fare As A Dividend Stock?

Opbrengsten en kosten

Hoe Pak Fah Yeow International geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

SEHK:239 Opbrengsten, kosten en inkomsten (HKD Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Jun 2426696570
31 Mar 24263101560
31 Dec 23260105550
30 Sep 2323897520
30 Jun 2321788490
31 Mar 2318359490
31 Dec 2214830480
30 Sep 2214428470
30 Jun 2214126470
31 Mar 2214132470
31 Dec 2114138470
30 Sep 2113129430
30 Jun 2112119400
31 Mar 21115-10390
31 Dec 20110-38390
30 Sep 20114-35460
30 Jun 20119-32530
31 Mar 201342530
31 Dec 1914836530
30 Sep 1916040540
30 Jun 1917145540
31 Mar 1915641540
31 Dec 1814237540
30 Sep 1814452430
30 Jun 1814766320
31 Mar 1816384330
31 Dec 17180103340
30 Sep 17183104330
30 Jun 17186106320
31 Mar 1718584310
31 Dec 1618361310
30 Sep 1617648310
30 Jun 1617034320
31 Mar 1617648320
31 Dec 1518361320
30 Sep 1518991340
30 Jun 15195122350
31 Mar 15191134340
31 Dec 14187146330
30 Sep 14176121310
30 Jun 1416496300
31 Mar 1416383290
31 Dec 1316271280

Kwaliteitswinsten: 239 has high quality earnings.

Groeiende winstmarge: 239's current net profit margins (36.3%) are lower than last year (40.6%).


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: 239's earnings have grown significantly by 42.9% per year over the past 5 years.

Versnelling van de groei: 239's earnings growth over the past year (9.4%) is below its 5-year average (42.9% per year).

Winst versus industrie: 239 earnings growth over the past year (9.4%) exceeded the Pharmaceuticals industry 6.4%.


Rendement op eigen vermogen

Hoge ROE: 239's Return on Equity (12.8%) is considered low.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden